

**REMARKS/ARGUMENTS**

This application is directed to Group II of the claims identified in the parent application in a restriction requirement.

A Sequence Listing has been added to the specification.

The disclosure has been amended in common with the parent case with respect to incorporation of material by reference on pages 1 and 4. The patent status of two of the pending US applications referred to on page 4 of the application has been noted.

An introductory paragraph has been added to page 1 reflecting the divisional status of this application and the claim to priority under 35 USC 119(e).

The claims have been amended to incorporate limitations effected in the parent filing. In particular, it is recited in the claims that the attenuated strain of bacteria harbours a vector comprising a nucleic acid molecule encoding at least one immuno-protection inducing *Chlamydia* protein or a fragment thereof which generates a *Chlamydia* protein specific immune response and a promoter operatively coupled to the nucleic acid molecule for expression of the *Chlamydia* protein or fragment thereof in cells of a host to which the strain is administered but not in the attenuated bacteria.

These changes have been made in the interests of expedited prosecution.

It is believed that this application is now in condition for allowance and early and favourable consideration and allowance are respectfully solicited.

Respectfully submitted,



---

Michael I. Stewart  
Reg. No. 24,973

Toronto, Ontario, Canada,  
(416) 595-1155  
FAX No. (416) 595-1163